← Eichor
Location: Los Angeles Synced from ClinicalTrials.gov · July 28, 2026

Clinical studies recruiting near Los Angeles

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Phase 3 · Children's Hospital Los Angeles - Endocrinology · Novo Nordisk A/S · NCT06612268
Multisite Advancement of Research on Chronic Posttraumatic Headache
NA · VA Greater Los Angeles Healthcare System · The University of Texas Health Science Center at San Antonio · NCT05620719
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 N
Phase 2/Phase 3 · Eikon Therapeutics · NCT07365319
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · Keck Medicine of USC Koreatown · National Cancer Institute (NCI) · NCT06029270
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard
Phase N/A · University of California Los Angeles (UCLA) · Regeneron Pharmaceuticals · NCT06693531
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · Children's Hospital of Los Angeles · Fred Hutchinson Cancer Center · NCT03779854
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Keck Medicine of USC Koreatown · National Cancer Institute (NCI) · NCT05987241
Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
NA · Los Angeles General Medical Center · University of Southern California · NCT06500169
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg
Phase 3 · Los Angeles Cancer Network · Gilead Sciences · NCT05633654
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · Children's Hospital Los Angeles ( Site 1006) · Merck Sharp & Dohme LLC · NCT06395103
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase N/A · Grand Avenue Surg Ctr · Stryker Instruments · NCT03072927
Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
Phase 4 · Children's Hospital Los Angeles (CHLA) · University of Michigan · NCT06671002
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Phase 2/Phase 3 · Kaiser Permanente Los Angeles Medical Center · DiaMedica Therapeutics Inc · NCT05065216
Real-Time Diagnosis of Life-Threatening Necrotizing Soft Tissue Infections (NSTI) Using Indocyanine Green (ICG) Kinetic
Phase N/A · University of California, Los Angeles · Eric R. Henderson · NCT06877793
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippo
Phase 3 · Kaiser Permanente Los Angeles Medical Center · NRG Oncology · NCT04804644
Randomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention Durin
NA · Stein Eye Institute - University of California Los Angeles · University of California, Los Angeles · NCT07715591
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 · Los Angeles Hematology Oncology Medical Group ( Site 0026) · Merck Sharp & Dohme LLC · NCT07060807
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Phase 2 · Children's Hospital Los Angeles · Healx Limited · NCT06541847
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C
Phase 3 · Kaiser Permanente Los Angeles Medical Center · National Cancer Institute (NCI) · NCT07061977
Phase 1 Pilot of a Pragmatic Trial of EAET for Veterans With Chronic Pain
NA · University of California, Los Angeles · University of California, Los Angeles · NCT07218757
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · Children's Hospital Los Angeles · Children's Oncology Group · NCT04851119
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Phase 4 · Amgen · NCT06072482
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I
Phase 3 · Children's Hospital Los Angeles · Boehringer Ingelheim · NCT07366034
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Kaiser Permanente Los Angeles Medical Center · SWOG Cancer Research Network · NCT04205968
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Phase 4 · Cedars-Sinai Medical Center · Duke University · NCT04262206
Stress Hydrocortisone In Pediatric Septic Shock
Phase 3 · Children's Hospital of Los Angeles · Jerry Zimmerman · NCT03401398
Follow-up Visit of High Risk Infants
Phase N/A · University of California - Los Angeles · NICHD Neonatal Research Network · NCT00009633
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-sm
Phase 3 · California Research Institute · Daiichi Sankyo · NCT06899126
Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans
NA · University of California Los Angeles · Duke University · NCT05120635
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
NA · University of California, Los Angeles · University of Colorado, Denver · NCT05753748
Look up another city
Look up another condition

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.